Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CGON - US1569441009 - Common Stock

43.34 USD
+0.04 (+0.09%)
Last: 12/8/2025, 11:45:16 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CGON. CGON was compared to 531 industry peers in the Biotechnology industry. CGON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CGON is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGON has reported negative net income.
In the past year CGON has reported a negative cash flow from operations.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CGON has a Return On Assets of -20.75%. This is in the better half of the industry: CGON outperforms 75.14% of its industry peers.
The Return On Equity of CGON (-22.03%) is better than 81.92% of its industry peers.
Industry RankSector Rank
ROA -20.75%
ROE -22.03%
ROIC N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

CGON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGON has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CGON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CGON has an Altman-Z score of 49.22. This indicates that CGON is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CGON (49.22) is better than 96.80% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CGON is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CGON is in line with its industry, outperforming 46.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 49.22
ROIC/WACCN/A
WACC8.78%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CGON has a Current Ratio of 22.79. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
CGON has a better Current ratio (22.79) than 96.42% of its industry peers.
A Quick Ratio of 22.74 indicates that CGON has no problem at all paying its short term obligations.
The Quick ratio of CGON (22.74) is better than 96.42% of its industry peers.
Industry RankSector Rank
Current Ratio 22.79
Quick Ratio 22.74
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.58% over the past year.
The Revenue has grown by 217.84% in the past year. This is a very strong growth!
CGON shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.09% yearly.
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)217.84%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%3774.42%

3.2 Future

The Earnings Per Share is expected to grow by 28.55% on average over the next years. This is a very strong growth
Based on estimates for the next years, CGON will show a very strong growth in Revenue. The Revenue will grow by 280.84% on average per year.
EPS Next Y-55.21%
EPS Next 2Y-39.71%
EPS Next 3Y-20.09%
EPS Next 5Y28.55%
Revenue Next Year82.98%
Revenue Next 2Y643.29%
Revenue Next 3Y398.18%
Revenue Next 5Y280.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGON. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

CGON's earnings are expected to decrease with -20.09% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.71%
EPS Next 3Y-20.09%

More info and screens

0

5. Dividend

5.1 Amount

CGON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CG ONCOLOGY INC

NASDAQ:CGON (12/8/2025, 11:45:16 AM)

43.34

+0.04 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-26 2026-03-26/bmo
Inst Owners103.25%
Inst Owner Change4.56%
Ins Owners0.66%
Ins Owner Change0%
Market Cap3.50B
Revenue(TTM)2.17M
Net Income(TTM)-151.48M
Analysts83
Price Target73.1 (68.67%)
Short Float %18.01%
Short Ratio14.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.55%
Min EPS beat(2)-15.32%
Max EPS beat(2)0.21%
EPS beat(4)1
Avg EPS beat(4)-14.42%
Min EPS beat(4)-33.19%
Max EPS beat(4)0.21%
EPS beat(8)3
Avg EPS beat(8)-71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1150.64%
Min Revenue beat(2)-100%
Max Revenue beat(2)2401.28%
Revenue beat(4)2
Avg Revenue beat(4)680.33%
Min Revenue beat(4)-100%
Max Revenue beat(4)2401.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.09%
PT rev (3m)15.59%
EPS NQ rev (1m)-2.98%
EPS NQ rev (3m)-2.37%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-0.45%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)-19.76%
Revenue NY rev (1m)698.67%
Revenue NY rev (3m)303.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1608.21
P/FCF N/A
P/OCF N/A
P/B 5.08
P/tB 5.19
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-2.77
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0.03
BVpS8.52
TBVpS8.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.75%
ROE -22.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.38%
Cap/Sales 15.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.79
Quick Ratio 22.74
Altman-Z 49.22
F-Score3
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-55.21%
EPS Next 2Y-39.71%
EPS Next 3Y-20.09%
EPS Next 5Y28.55%
Revenue 1Y (TTM)217.84%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%3774.42%
Revenue Next Year82.98%
Revenue Next 2Y643.29%
Revenue Next 3Y398.18%
Revenue Next 5Y280.84%
EBIT growth 1Y-88.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-83.94%
EBIT Next 3Y-32.29%
EBIT Next 5YN/A
FCF growth 1Y-221.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-220.44%
OCF growth 3YN/A
OCF growth 5YN/A

CG ONCOLOGY INC / CGON FAQ

Can you provide the ChartMill fundamental rating for CG ONCOLOGY INC?

ChartMill assigns a fundamental rating of 3 / 10 to CGON.


What is the valuation status of CG ONCOLOGY INC (CGON) stock?

ChartMill assigns a valuation rating of 0 / 10 to CG ONCOLOGY INC (CGON). This can be considered as Overvalued.


What is the profitability of CGON stock?

CG ONCOLOGY INC (CGON) has a profitability rating of 1 / 10.


What is the financial health of CG ONCOLOGY INC (CGON) stock?

The financial health rating of CG ONCOLOGY INC (CGON) is 6 / 10.